Europe In Vitro Diagnostics (IVD) Market Expected to Reach $18 Billion by 2027

 

According to a new report published by Allied Market Research, titled, "Europe In Vitro Diagnostics Market by Product& Service, Technique, Application, and End User: Opportunity Analysis and Industry Forecast, 2019–2026,"the Europein vitro diagnostics market was valued at $13 billion in 2019, and is expected to reach $18 billion by 2027, registering a CAGR of 4.8% from 2019 to 2027. 

 

In vitro diagnostics is defined as medical devices which are used by laboratories to perform diagnostic tests. These tests are performed on samples collected from a patient’s body such as blood, urine, and tissues. Furthermore, medical devices used to perform in vitro diagnosis also require the use of various technologies to conduct tests. For instance, blood collected from a patient is analyzed for hepatitis infection by using enzyme linked immunosorbent assay technique to analyze the blood. Furthermore, the testing procedure also requires use of various chemicals & reagents and software for smooth operations. In addition, in vitro diagnostics are used for detection of various medical conditions such as infectious diseases, diabetes, oncology/cancer, cardiology diseases, autoimmune diseases, nephrology, and HIV/AIDS. Moreover, these tests are performed in various medical facilities such as hospitals, standalone laboratories, and academic & medical schools. 

 

Click Here To Access Sample Report: https://www.alliedmarketresearch.com/request-sample/4352

 

Factors such as rise in awareness about healthcare, surge in incidences of chronic and infectious disease, and cost-effective diagnostic solutions boost growth of the Europe in vitro diagnostics market. Similarly, rise in use of automated instruments, surge in government expenditure on healthcare in Europe, and accurate and faster test results supplement the growth of the market. However, stringent regulations & policies and unclear reimbursement rules hamper the market growth. Moreover, potential for outsourcing present lucrative opportunities for key players in the Europe in vitro diagnostics market during the forecast period.

The report segments the market into product & service, technique, application, end user, and region. On the basis of product & service it is segmented into chemicals & reagents, instruments, and services & software. On the basis of technique, it is categorized into immunodiagnostics, hematology, molecular diagnostics, tissue diagnostics, clinical chemistry, and others. In addition, the immunodiagnostics segment is further divided into types such as enzyme-linked immunosorbent assay (ELISA), rapid tests, enzyme-linked immunospot (ELISPOT), radioimmunoassay (RIA), and western blot. Moreover, the ELSIA segment is further divided into chemiluminescence immunoassay (CLIA), fluorescence immunoassay (FIA), and colorimetric immunoassay (CI). Similarly, the molecular diagnostics segment is divided into polymerize chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT), hybridization, DNA diagnostics, microarray, and others. 

 

On the basis of application, the market segmented into infectious diseases, cancer, cardiac diseases, immune system disorders, nephrological diseases, gastrointestinal diseases, and others. On the basis of end user, it is categorized into standalone laboratories, hospitals, academics & medical schools, point-of-care, and others. Country wise, the market is analyzed across Germany, France, the UK, Italy, Spain, and rest of Europe

 

The clinical chemistry segment is also further divided basic metabolic panel, liver panel, lipid profile, thyroid function panel, electrolyte panel, specialty chemicals, and others. 

 

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/4352

 

Key Findings Of The Study 

·         The reagents segment accounted for more than half of the share of the Europe in vitro diagnostics market in 2019.

·         The instruments segment is expected to grow at the highest CAGR from 2020 to 2027.

·         The infectious diseases segment accounted for around one-thirds share of the Europe in vitro diagnostics market in 2019.

·         Germany accounted for around one-fifth share of the Europe in vitro diagnostics market in 2019.

·         UK is expected to provide lucrative growth opportunities from 2019 to 2027.

North America IVD Market Expected to Reach $27,820 million by 2023

 

According to a new report published by Allied Market Research, titled, North America IVD Market by Product Type, Techniques, Application and End-Users: Global Opportunity Analysis and Industry Forecast, 2017-2023., North America IVD market was valued at $20,886 million in 2016, and is projected to reach at $27,820 million by 2023, growing at a CAGR of 4.1% from 2017 to 2023.

Click Here To Access Free Sample Report: https://www.alliedmarketresearch.com/request-sample/4347

 

 In vitro diagnostics are medical devices utilized to examine biological samples such as blood, urine, stool, tissues, and other body fluids. The tests can be performed in standalone laboratory, and hospital-based laboratory. Some of the significant technologies incorporated in vitro diagnostics include polymerase chain reaction, microarray techniques, sequencing technology and mass spectrometry, which are used for test sample preparation.

Based on product type, the reagents segment held the highest market share in 2016, owing to the recent introduction of new novel reagents in the market that are more effective.
Based on technique, the immunodiagnostics segment contributed the highest market share in 2016, due to the increase in prevalence of chronic diseases and increase in awareness of personalized medicine among the population.

Based on application, the infectious diseases segment contributed the highest market share in 2016, owing to the increase in prevalence of infectious diseases and rise in healthcare expenditure.

Based on end users, the standalone laboratory segment captured the highest market share in 2016, due to increase healthcare expenditure and improving healthcare facilities
By country, it is analyzed across the U.S., Canada, and Mexico. The U.S. was the highest revenue contributor in 2016. This is attributed to high expenditure in healthcare, well-established healthcare system, and high incidence of chronic diseases. However, Mexico is projected to be grow with the highest CAGR during the analysis period, owing to rise in healthcare expenditure, increase in per capita income, and improvement in healthcare infrastructure.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/4347

 Key Findings of the North America IVD Market:

• The reagents segment dominated the market in 2016, and is projected to grow at the 3.1% CAGR.
• The immunodiagnostics segment accounted for the highest share in 2016.
• The infectious diseases segment was the major shareholder in 2016.
• The standalone laboratory segment accounted for the highest share in 2016.
• The U.S was the major shareholder in 2016.
• Mexico is expected to grow at the highest CAGR in the market.

Major companies operating in this market adopt product launch as their key development strategy. Companies profiled in this market include, Thermo Fisher Scientific Inc., Alere Inc., Biomerieux, Danaher Corporation, F. Hoffmann-La Roche AG, Becton Dickinson and Company, Bio-Rad Laboratories, Bayer AG, Sysmex Corporation, and Johnson & Johnson among others.

Automatic Pill Dispenser Machine Market Expected to Reach $3,023 million by 2023

 

According to a new report published by Allied Market Research, titled, Automatic Pill Dispenser Machine Market by Type and Application: Global Opportunity Analysis and Industry Forecast, 2017-2023, the global automatic pill dispenser machine market was valued at $1,755 million in 2016, and is projected to reach $3,023 million by 2023, growing at a CAGR of 8% from 2017 to 2023. The centralized automated dispensing systems segment held more than four-fifths share of the total market in 2016.

Click Here To Access Free Sample Report: https://www.alliedmarketresearch.com/request-sample/4329

 

 Automatic pill dispenser machines are designed to dispense different pills independently according to the user-defined dose and time specifications. The automatic pill dispenser machine support to dispense correct medication and dose, for the patients with complex medication regime and with memory loss disorders.

Based on the type, the centralized automated dispensing systems segment held the highest market share in 2016, owing to various benefits of the machines such as point-of-care availability, their capability to control storage & distribution, and maintain record of medicines.

Based on application, the hospital pharmacy segment contributed the highest market share in 2016, owing to the increase in need of fast and accurate dispensing of medicines in the hospitals and pharmacy.

North America accounted for more than half of the share in 2016, and is expected to dominate the market throughout the forecast period and is attributed to rise in expenditure to upgrade healthcare systems and growth in demand for technologically advanced devices for rapid & accurate distribution of medicines. In addition, lucrative growth opportunities in the economic emerging countries is anticipated to provide new growth opportunities for the key players in the market. However, Asia-Pacific is estimated to register the highest growth rate during the forecast period, owing to rise in government healthcare expenditure and growth in demand for healthcare devices from large pool of patient population, and improvement in healthcare infrastructure.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/4329

 Key Findings of the Automatic Pill Dispenser Machine Market:

• By type, the centralized automated dispensing system segment dominated the market in 2016, and is projected to grow at the highest CAGR.
• By application, the hospital pharmacy segment accounted for the highest share in 2016.
• The U.S. was the major shareholder in the North America cardiac surgical devices market in 2016.
• Asia-Pacific is expected to show the highest growth rate during the analysis period.
• China is expected to grow at the highest CAGR in the Asia-Pacific market.

Major companies operating in this market adopt product launch as their key development strategy. Companies profiled in this market include, Baxter International Inc., Becton, Dickinson and Company, Cerner Corporation, Capsa Healthcare, McKesson Corporation, Omnicell Inc., ScriptPro LLC, Swisslog Holdings AG, Talyst, Inc., and Yuyama Co., Ltd.

Other prominent players in the value chain include Illinois Tool Works, Pearson Medical Technologies, Accu-Chart Plus Healthcare System, Allscripts Healthcare Solutions, Inc., Meditech, Constellation Software Inc., and Optum Inc.

Peripheral artery disease Market Expected to reach $4,980 Million by 2023

 

According to a new report published by Allied Market Research, titled, "Peripheral Artery Disease Market by Type: Global Opportunity Analysis and Industry Forecast, 2017-2023," the global peripheral artery disease market was valued at $3,136 million in 2016, and is projected to reach $4,980 million by 2023, growing at a CAGR of 6.8% from 2017 to 2023. The peripheral stents segment held more than two-fifth share of the total market in 2016.

Click Here To Access Free Sample Report: https://www.alliedmarketresearch.com/request-sample/4315

 

Peripheral artery disease is a circulatory disease in which plaque builds up in the arteries of legs, heads, and other limbs. Increase in geriatric population and rise in number of patients suffering from peripheral artery disease, are expected to drive the market growth. Moreover, favorable reimbursement scenario for peripheral artery disease treatment and advanced peripheral treatment products such drug-eluting stents in turn boosts the market growth. However, restenosis (reoccurrence of peripheral artery disease post treatment) is expected to impede the market growth.

Peripheral stents segment is expected to dominate the market throughout the analysis period as these significantly reduce the risk associated with the build-up of plaque in the arteries. Plaque modification devices is expected to register highest CAGR of 7.6% during the forecast period.

Key Findings of the Peripheral Artery Disease Market:

• Atherectomy devices is projected to grow at a CAGR of 7.9% during the forecast period.
• Chronic total occlusion devices accounted for more than two-fifth of the share of the global peripheral artery disease market, in 2016.
• Aspiration thrombectomy segment is expected to register the highest CAGR of 10.3% during the analysis period.
• Drug-eluting stents is expected to grow at the CAGR of 7.7% during the forecast period.
• France and Germany collectively contributed for more than one-third share of the European peripheral artery disease market in 2016.
• Japan is the major shareholder, accounting for more than one-third share of the Asia-Pacific peripheral artery disease market in 2016.

 

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/4315

 

Asia-Pacific is projected to register the highest CAGR of 7.9% during the forecast period, owing to increase in incidence of population suffering from diabetes, obesity, and high blood pressure. In addition, increase in healthcare expenditure and introduction of interventional products such as drug-coated balloon offer a lucrative opportunity for the market growth.

The major companies profiled in the report include Abbott Laboratories, Boston Scientific Corporation, Cook Medical, Cardinal Health, Inc., C. R. Bard, Inc., Medtronic plc, Terumo Corporation, The Spectranetics Corporation, AngioDynamics, Inc., BIOTRONIK, and B. Braun Melsungen AG.

Operating Room Equipment Market to Reach $33,307 Million by 2023

 

According to a new report published by Allied Market Research, titled, "Operating Room Equipment Market by Treatment Type and End User: Global Opportunity Analysis and Industry Forecast, 2017-2023, " the global operating room equipment market was valued at $24,192 million in 2016, and is projected to reach $33,308 million by 2023, growing at a CAGR of 4.5% from 2017 to 2023. North America is anticipated to be the highest revenue contributor throughout the forecast period.

Click Here To Access Free Sample Report: https://www.alliedmarketresearch.com/request-sample/4237

 

Operating rooms (OR) or operating theatres are designed for surgeons and surgical staff to perform surgical procedures that require time, patience, focus, and safety. The equipment used in OR consists of surgical imaging devices, anesthesia machines, electrosurgical devices, operating room lights, operating room tables, and others. Quality OR equipment plays a pivotal role in surgical settings as they streamline the workflow in the OR.

Increase in global elderly population & rise in number of hospitals boost the market growth. In addition, rise in preference for minimally invasive surgeries and growth in regulatory approvals with respect to OR equipment is expected to drive the operating room equipment market. However, high cost associated with OR equipment and unfavorable healthcare reforms, especially in the U.S., are projected to impede the market growth.

Electrosurgical devices is anticipated to be the fastest growing segment throughout the analysis period owing to increase in the number of surgical procedures. Furthermore, the ambulatory surgical centers segment is projected to be the fastest growing end user segment with a CAGR of 6.2% from 2017 to 2023, owing to cost effective yet critically appropriate settings offered by these centers.

By geography, the market was dominated by North America in 2016, and is expected to maintain its lead throughout the forecast period. North America and Asia-Pacific collectively accounted for ~63% of the overall operating room equipment market in 2016. The growth of these regions is attributed to the availability of affordable medical treatments for several disease conditions, in countries such as Mexico, Thailand, Malaysia, India, and Singapore. However, Asia-Pacific is the fastest growing region followed by LAMEA, owing to the increase in treatment success rates and the affordable price range with respect to surgical procedures.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/4237

Key Findings of the Operating Room Equipment Market:

• In 2016, surgical imaging devices generated the highest revenue, accounting about two-fifths of the overall market revenue and is projected to grow at a CAGR of 2.4% during the forecast period.
• Electrosurgical devices is expected to grow at an above-average CAGR of 7.8%, owing to increased number of skilled medical personnel in the field.
• North America accounted for more than 40% of the market share in 2016.
• Asia-Pacific is anticipated to be the fastest growing market during the analysis period, followed by LAMEA.

The major companies profiled in the report include Steris Corporation, Stryker Corporation, Koninklijke Philips N.V., Getinge Group, Hill-Rom Holdings, Inc., Drgerwerk AG & Co. KGaA, General Electric Company, Medtronic, plc, Mizuho SOI, and Karl Storz GmbH & Co. Kg.

 

Antibacterial Coatings Market for Medical Implants Expected to Reach $343 Million by 2023

 

According to a new report published by Allied Market Research, titled, "Antibacterial Coatings Market for Medical Implants: Global Opportunity Analysis and Industry Forecast, 2017-2023," the market was valued at $120.22 million in 2016, and is projected to reach $343.16 million by 2023, registering a CAGR of 16.1% from 2017 to 2023. Metallic coatings segment held around three-fourths share of the total market in 2016.

Antibacterial coatings are materials that prevent the bacterial adhesion and biofilm formation on the surface of medical implants. In addition, they act as anti-thrombotic coating, which prevents the formation of thrombus during bacterial infections after the surgery in patient. So accordingly, medical implants are coated with antibacterial coating to obtain an ideal potent surface that can provide protection against the pathogens.

Click Here To Access Free Sample Report: https://www.alliedmarketresearch.com/request-sample/4462

 

The major factors that drive the global antibacterial coatings market for medical implants are increase in incidence of implant-associated infections, demand for implantable devices, rise in bone related and cardiovascular disorders, and growth of geriatric population. However, high cost of antibacterial coatings, few drawbacks of silver coatings, and time-consuming regulatory approvals are expected to restrain the market growth. Conversely, growth in need of better healthcare services in the emerging markets, such as China and India, and development of novel antibacterial coatings are expected to provide lucrative opportunities to the market players.

The metallic coatings segment occupied the highest share in 2016, owing to the usage applicability and availability of metallic coatings in medical & clinical settings. Furthermore, the metallic coating segment is expected continue its dominance in the market during the forecast period. The utilization rate of antibacterial coating for cardiac implants is high, however orthopedic implants is expected to grow at a high CAGR during the forecast period. This is attributed to increase in incidence of bone related disorders such as fractures or replacement of joints leading rise in use of orthopedic implants.

Key Findings of the Antibacterial Coatings Market:

• Non-metallic coating segment is expected to grow at a CAGR of 13.8% from 2017 to 2023.
• Metallic coatings segment accounted for around three-fourths share of the global antibacterial coatings market for medical implants in 2016.
• Cardiac implants segment accounted for more than one-fifth share of the global antibacterial coatings market for medical implants in 2016.
• Asia-Pacific is expected to grow at the highest CAGR of 17.4%, from 2017 to 2023.
• North America accounted for around one-third share of the global antibacterial coatings market for medical implants in 2016.

 

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/4462

 

North America was the leading revenue contributor to the global antibacterial coatings market for medical implants. This is attributed to the early adoption of technologically advanced coating and high use of implantable devices due to rise in incidence of chronic disorders. However, Asia-Pacific is expected to grow at the highest CAGR during the study period, due to increase in affordability, surge in healthcare expenditure, and growth in awareness about implantation surgeries.

The major companies profiled in the report are aap Implantate AG, AST Products, Inc., BioCote Ltd, Covalon Technologies Ltd., DOT GmbH, Harland Medical Systems Inc., Hydromer, Inc., Koninklijke DSM N.V., Sciessent LLC, and Specialty Coating Systems, Inc.

 

PET-CT Scanner Device Market to Reach $2,108 Million, Globally by 2023

According to a new report published by Allied Market Research, titled, PET-CT Scanner Device Market by Application, Service Provider, Type, Slice Count, and Isotopes: Global Opportunity Analysis and Industry Forecast, 2017-2023, the global PET-CT scanner device market was valued at $1,454 million in 2016, and is projected to reach $2,108 million by 2023, growing at a CAGR of 5% from 2017 to 2023. The oncology segment held more than five-sixth share of the total market in 2016.

Click Here To Access Free Sample Report: https://www.alliedmarketresearch.com/request-sample/4422

 

Many diseases such as cancer, cardiovascular, certain infectious, and brain disorders require both positron emission tomography (PET) and computed tomography (CT) scans for proper diagnosis of diseases. PET scanner measures metabolic activity, whereas CT scanners highlight anatomical features of the body. PET-CT scanner combines the strength of both scanners enabling more accurate diagnosis as well as localizing and monitoring the diseases. It also reduces space of imaging facilities & less time for physician to elevate the scans.

Based on the application, the oncology segment held the highest market share in 2016, owing to rise in incidences of cancer globally. Based on service provider, the hospital segment contributed the highest market share in 2016, owing to the increase number of hospitals and large pool of skilled personnel available in hospital. Based on type, the market is classified into stationary scanners segment, contributed the highest market share in 2016, owing to high cost and reliability of the devices. Based on slice count, the Medium Slice Scanner (64 Slices) scanner segment contributed the highest market share in 2016, owing to the high usage.

Based on isotopes, the Flurodeoxyglucose (FDG) segment contributed the highest market share in 2016, owing to its application of detection of various diseases such as oncology, cardiology, and neurology.

Asia-Pacific accounted for more than two-fifth of the share in 2016, and is expected to dominate the market throughout the forecast period and is attributed to rise in expenditure to upgrade healthcare systems and growth in demand for technologically advanced devices. In addition, lucrative growth opportunities in the economic emerging countries is anticipated to provide new growth opportunities for the key players in the market. In addition, Asia-Pacific is estimated to register the highest growth rate during the forecast period, owing to rise in government healthcare expenditure and growth in demand for healthcare devices from large pool of patient population, and improvement in healthcare infrastructure.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/4422

 Key Findings of the PET-CT Scanner Device Market:

• By application, the oncology segment dominated the market in 2016, and is projected to grow at the highest CAGR.
• By service provider, the hospital segment accounted for the highest share in 2016.
• By type, the stationary scanners segment is anticipated to grow at the highest CAGR.
• By slice count, the medium slice scanner (64 Slices) accounted for the highest share in 2016.
• By isotopes, the FDG accounted for the highest market share of eight-ninth in 2016.
• The U.S. was the major shareholder in the North America PET-CT scanner device market in 2016.
• Asia-Pacific is expected to show the market share and highest growth rate during the analysis period.
• India is expected to grow at the highest CAGR in the Asia-Pacific market.

Major companies operating in this market adopt product launch as their key development strategy. Companies profiled in this market include Toshiba Corporation, General Electric Co, Hitachi, Ltd., Koninklijke Philips N.V., Shimadzu Corporation, Siemens AG, PerkinElmer, Inc., Positron Corporation, Yangzhou Kindsway Biotech Co. Ltd. and Mediso Ltd.

Other prominent players in the value chain include NeuroLogica Corporation, NaturSoft Medical Systems Co., Ltd., Shenzhen Anke High-Tech, Trivitron Technologies, and Shenzhen Anke High-tech Co.

BCG Vaccine Market Expected to Reach $28,051 Thousand, Globally, by 2023

 

According to a new report published by Allied Market Research, titled, BCG Vaccine Market by Demographics: Global Opportunity Analysis and Industry Forecast, 2017-2023," the global BCG vaccine market was valued at from $20,366 thousand in 2016, and is estimated to reach $28,051 thousand by 2023, growing at a CAGR of 4.6% from 2017 to 2023. The Indian BCG vaccines market holds the highest share in the global BCG vaccines market.

Click Here To Access Free Sample Report: https://www.alliedmarketresearch.com/request-sample/4419

 

Bacillus Calmette-Gurin (BCG) vaccine is the only vaccine currently available for prevention of tuberculosis (TB). One dose of BCG vaccine is recommended for healthy babies at birth in countries where tuberculosis is common.

The major factor that contributes to the market growth are increase in incidence rate of tuberculosis in developing nations, rise in R&D activities related to vaccines, and growth in government initiatives and focus on immunization programs globally. However, side reactions of BCG vaccines on patients and shortage of vaccine supply hinder the market growth. Moreover, untapped market opportunities in developing regions are expected to provide numerous opportunities for market growth.

The pediatrics segment is expected to maintain its dominant position during the analysis period, as the vaccine is administered to all the children at the time of birth. As BCG is recommended for only one dose; therefore, it is used rarely in the case of adults.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/4419

 

Key Findings of the BCG Vaccine Market:

• The pediatrics segment accounted for more than three-fourths share of the global market in 2016.
• China is expected to grow at a rapid CAGR of 6.2% from 2017 to 2023.
• India accounted for one-sixth of the global market in 2016.
• The adults segment is expected to grow at a CAGR of 3.6% from 2017 to 2023.

The major companies profiled in the report include Merck & Co., Inc., Sanofi Pasteur, Japan BCG Laboratory, China National Biotec Group (a subsidiary of China National Pharmaceutical Group Corporation), Serum Institute of India Pvt. Ltd., InterVax Ltd., GreenSignal Bio Pharma Limited (GSBPL), and Statens Serum Institut.

 

Ureteral Stents Market Expected to Reach $ 449 Million, Gloabally, by 2023

 

According to a new report published by Allied Market Research, titled, UreteralStents Market by Product, Material, Application, and End User: Global Opportunity Analysis and Industry Forecast, 2017-2023, the global ureteral stents market was valued at $304 million in 2016, and is estimated to reach $449 million by 2023, growing at a CAGR of 5.7% from 2017 to 2023. The double pigtail stents segment held the highest market share in 2016.

 

Click Here To Access Free Sample Report: https://www.alliedmarketresearch.com/request-sample/4414

 

Ureteral stents are used to enable the drainage of urine from blocked ureters in the case of various urological disorders such as kidney stones, tumors, urinary incontinence, and kidney transplantation.

Constant technological developments, rise in incidence of urological diseases, and increase in medical tourism in the developing countries drive the growth of the market. However, lack of skilled urologists and complications related to ureteral stents are expected to limit the market growth.

The global ureteral stents market is segmented based on product, material, application, end user, and geography. On the basis of product, the double pigtail stents segment held the highest market share in 2016, owing to increased use of these instruments in surgical procedures.

By material, Metallic Stents segment held the highest market share in 2016, and Polymer Stents segment is expected to grow at the highest rate, registering the CAGR of 8.2% by 2023.

Based on application, metallic stents segment held the largest market share in 2016, due to increase in geriatric population and sedentary lifestyle.

Based on end user, hospitals have witnessed the highest number of urological surgeries, thus accounting for the highest market share in 2016.

Key Findings Of The Ureteral Stents Market:

• Double pigtail stents segment dominated the market in 2016, and multiloop stents segment is projected to grow at the highest CAGR during the forecast period.
• The metallic stents segment accounted for the highest share in 2016.
• U.S. was the major shareholder in the North American ureteral stents market in 2016.
• Asia-Pacific is expected to register the highest growth rate in future.
• India is expected to grow at the highest CAGR in the Asia-Pacific ureteral stents market.

 

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/4414

 

North America accounted for two-fifths share in 2016, and is expected to dominate the market throughout the forecast period. This is attributed to the presence of well-established healthcare systems and increase in prevalence of diseases, such as kidney stones and tumors. In addition, higher adoption rate for technologically advanced devices is anticipated to provide new growth opportunities for the key players in the North American market. However, Asia-Pacific is projected to grow at the highest growth rate during the analysis period, owing to rise in healthcare expenditure, increase in per capita income, growth in demand for healthcare services from a large patient pool, and improvement in healthcare infrastructure.

The major players profiled in the global ureteral stents market are Boston Scientific Corporation, B. Braun Holding GmbH & Co. KG, Cook Group Incorporated, C. R. Bard, Inc., Coloplast Ltd., Medline Industries, Inc., Allium Medical Solutions Ltd., Pnn Medical A/S, Teleflex Incorporated, and Olympus Corporation.

 

Idiopathic Pulmonary Fibrosis Market to Reach $3,569 Million, Globally by 2023

 

According to a new report published by Allied Market Research, titled, IdiopathicPulmonary Fibrosis Market by Type of Drug: Global Opportunity Analysis and Industry Forecast, 20172023, the global idiopathic pulmonary fibrosis market was valued at $1,616 million in 2016, and is projected to reach $3,569 million by 2023, growing at a CAGR of 11.9% from 2017 to 2023. Perifenidone held more than half share of the total market in 2016.

 

Click Here To Access Free Sample Report: https://www.alliedmarketresearch.com/request-sample/4407

 

Idiopathic pulmonary fibrosis is a disease in which lung tissues become thick and stiff over time, which results in reducing the oxygen carrying capacity of the tissues. Increase in geriatric population and rise in number of patients suffering from idiopathic pulmonary fibrosis are expected to drive the market growth. In addition, rise in frequency of cigarette smoking population boosts the market growth. However, unavailability of the treatment options that can completely cure the disease restricts the market growth.

Perifenidone is expected to dominate the market throughout the analysis period, as this medication helps to slow scarring, and thus preserve lung function. Nintedanib is expected to register highest CAGR of 12.2% during the forecast period.

Key Findings of the Idiopathic Pulmonary Fibrosis Market:

• Nintedanib is projected to grow at a CAGR of 12.2% during the forecast period.
• Pirfenidone accounted for more than half of the share of the global idiopathic pulmonary fibrosis market in 2016.
• France and Germany collectively contributed for more than one-third share of the European idiopathic pulmonary fibrosis market in 2016.
• Japan was the major shareholder in 2016, accounting for more than one-third share of the Asia-Pacific idiopathic pulmonary fibrosis market.
• Brazil is the major shareholder in 2016, accounting for nearly than one-fourth share of the LAMEA idiopathic pulmonary fibrosis market.

 

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/4407

 

Asia-Pacific is projected to register the highest CAGR of 13.0% during the forecast period, owing to increase in incidence of population suffering from fibrotic disease and rise in ageing population. In addition, increase in healthcare expenditure offers a lucrative opportunity for the market growth.

The major companies profiled in the report include MediciNova, Inc., Boehringer Ingelheim, F. Hoffmann-La Roche, FibroGen, Inc., Promedior, Inc., Merck & Co., Inc., Galapagos NV, Biogen, Bristol-Myers Squibb Company, Prometic Life Sciences Inc., and Cipla Inc.

 

Womens Health Diagnostics Market to Hit $21,502 Million by 2023

 According to a new report published by Allied Market Research, titled, Women's Health Diagnostics Market, by Type and End User: Global Opportunity Analysis and Industry Forecast, 2017-2023," the global women's health diagnostics market was valued at $13,133 million in 2016, and is projected to reach $21,501 million in 2023 at a CAGR of 7.0% from 2017 to 2023.

 

Gynecology is the main branch of medical science concerned with women's health problems. This includes the health related disorders, their screening and testing procedures. Women are highly prone to various cancers such as breast, cervical, and ovarian cancer. Other health issues include infertility, polycystic ovarian syndrome, menopause, depression, osteoporosis, and obesity.

 

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/4521

 

Factors such as rise in prevalence of various chronic lifestyle disorders in women, rise in female geriatric population who are more prone to several disorders, increase in adoption of point of care diagnosis, high demand for imaging and diagnosing centers, and support from government in promoting awareness about women related disorders. However, factors such as expensive imaging procedures and lack of skilled professionals restrains the market growth. Conversely, huge untapped market potential in the emerging countries, such as South Africa and India, and development of novel and advanced imaging procedures such as miniature devices are expected to provide lucrative opportunities to the market players.

 

The diagnostic tests segment occupied the largest share in 2016, owing to the high usage, applicability, and availability of tests for detecting various disorders in women. Furthermore, the accessories and consumables segment is expected to grow at the highest CAGR of 7.8% from 2017 to 2023, and is anticipated to continue its dominance during the forecast period. The utilization rate of various women's health related diagnostics procedures for hospitals and clinics is high, however diagnostic and imaging centers segment is expected to grow at a CAGR of 7.8% during the forecast period. This is attributed to increase in incidence of various types of health-related disorders.

 

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/4521

 

Key findings of the Women's Health Diagnostics Market:

• Diagnostic tests segment accounted for around 55.1% share of the global women's health diagnostics market in 2016
• Diagnostic devices segment is expected to grow at a CAGR of 6.5% from 2017 to 2023.
• Hospitals and clinics segment accounted for around 49.8% share of the global women's health diagnostics market in 2016
• North America accounted for around 33.7% share of the global women's health diagnostics market in 2016
• Asia-Pacific is expected to grow at the highest CAGR of 8.1% from 2017 to 2023

 

North America was the leading revenue contributor to the global women's health diagnostics market, accounting for nearly one-third of the global market. This is attributed to the presence of numerous screening tests for cancer detection and other diseases. Moreover, presence of key players and advanced diagnostics procedures such as 3D mammography. However, Asia-Pacific is expected to grow at the highest CAGR of 8.1% during the study period, due to increase in affordability, surge in healthcare expenditure, and rise in awareness towards various women related disorders.